arsenic trioxide has been researched along with Cancer, Second Primary in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, S; Avagyan, A; Bird, ST; Blumenthal, G; Chuk, M; de Claro, RA; Deisseroth, AB; Farrell, AT; Graham, DJ; Kelman, JA; Li, Y; Liao, J; MaCurdy, TE; Norsworthy, KJ; Pazdur, R; Swain, R; Wernecke, M | 1 |
| Baer, MR; Benner, A; Burnett, AK; Ehninger, G; Elliott, MA; Estey, EH; Gonzales, P; Görner, M; Grimwade, D; Hills, RK; Ho, AD; Kayser, S; Krämer, A; Krzykalla, J; Levis, MJ; Mayer, J; Norsworthy, K; Novak, J; Platzbecker, U; Ráčil, Z; Röllig, C; Russell, NH; Schlenk, RF; Smith, BD; Szotkowski, T; Tallman, MS; Thiede, C; Walter, RB; Westermann, J; Žák, P | 1 |
| Kayser, S; Platzbecker, U; Schlenk, RF | 1 |
| Au, WY; Fong, BM; Lang, BH; Mao, KJ; Tam, S | 1 |
| Hasan, SK; Lo-Coco, F; Montesinos, P; Sanz, MA | 1 |
| Firkin, F | 1 |
| Hasan, SK; Lo-Coco, F | 1 |
| Feusner, JH; Gregory, J; Kutny, MA | 1 |
| Cortes, J; Daver, N; Eghtedar, A; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Rodriguez, I | 1 |
| Béné, MC; Bonnet, A; Chevallier, P; Garandeau, C; Garnier, A; Guillaume, T; Houreau-Langlard, D; Hourmant, M; Le Gouill, S; Moreau, P; Peterlin, P; Tissot, A; Vantyghem, S | 1 |
| Ravandi, F | 2 |
| Advani, A; Afable, M; Chan, J; Englehaupt, R; Erba, HP; Kalaycio, ME; Maciejewski, JP; Seel, S; Sekeres, MA; Sobecks, R | 1 |
| Au, WY; Chim, CS; Chung, LP; Kwong, YL; Ma, SK | 1 |
| Boehlke, L; Frater, JL; Nabhan, C; Parmar, S; Raji, A; Riley, M; Rundhaugen, LM; Tallman, MS | 1 |
| Au, WY; Fong, BM; Kwong, YL; Tam, S; Wan, TS; Yip, SF | 1 |
| Carmignani, A; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Testi, R | 1 |
| Chan, P; Huff, J; Nyska, A; Waalkes, M | 1 |
4 review(s) available for arsenic trioxide and Cancer, Second Primary
| Article | Year |
|---|---|
Management of patients with acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Electrocardiography; Female; Fetus; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasms, Second Primary; Pregnancy; Recurrence; Renal Dialysis; Renal Insufficiency; Tretinoin | 2018 |
Biology and management of therapy-related acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Early Diagnosis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Retrospective Studies; Risk Factors; Tretinoin | 2013 |
Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Disease Models, Animal; DNA End-Joining Repair; Drug Synergism; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2014 |
Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Age of Onset; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Coagulation Disorders; Bone Marrow Examination; Cell Differentiation; Child; Child, Preschool; Heart Diseases; Humans; Infant; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm, Residual; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Oxides; Prognosis; Pseudotumor Cerebri; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Tretinoin | 2014 |
2 trial(s) available for arsenic trioxide and Cancer, Second Primary
| Article | Year |
|---|---|
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome | 2011 |
Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
Topics: Acute Disease; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; Bone Marrow Examination; Disease Progression; Drug Resistance, Multiple; Female; Glycoproteins; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome | 2004 |
12 other study(ies) available for arsenic trioxide and Cancer, Second Primary
| Article | Year |
|---|---|
Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Medicare; Neoplasms, Second Primary; Prognosis; SEER Program; United States | 2020 |
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Carcinoma, Papillary; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Thyroid Cancer, Papillary; Thyroid Gland; Thyroid Neoplasms; Young Adult | 2014 |
Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Carcinoma, Papillary; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Tretinoin; Young Adult | 2015 |
Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Lung Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Postoperative Complications; Skin Neoplasms; Tretinoin | 2016 |
Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medical Oncology; Neoplasms, Second Primary; Oxides; Translocation, Genetic; Treatment Outcome; Tretinoin | 2009 |
Therapy-related acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Radiotherapy, Computer-Assisted | 2011 |
Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Male; Neoplasms, Second Primary; Oxides; Pregnancy; Tretinoin | 2002 |
Second hematological malignancies during arsenic trioxide therapy of B-cell lymphomas.
Topics: Aged; Arsenic Trioxide; Arsenicals; Female; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Male; Neoplasms, Second Primary; Oxides | 2009 |
Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Oxides; Recurrence; Transplantation, Autologous; Tretinoin | 1999 |
Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lymphocytes; Neoplasms, Second Primary; Oxides | 1999 |